AI identifies semapimod against dormant bacteria
A machine-learning system selected semapimod, a known anti-inflammatory drug, for activity against dormant Gram-negative bacteria. MIT reports laboratory activity against E. coli and A. baumannii and an effect that sensitizes these bacteria to other antibiotics; the result is preclinical and does not demonstrate efficacy in patients.
Technology: Machine learning for compound screening
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Lab-only time-lapse microscopy of E. coli treated with semapimod showed activity against stationary-phase E. coli and A. baumannii and sensitization to other antibiotics.
- Still unknown: The article states no limitations, no animal or patient testing is mentioned, and no drug combinations are named.
- AI role: AI-based high-throughput screening of known drug compounds identified semapimod for antibiotic activity.
Evidence sources: https://news.mit.edu/2024/mit-scientists-are-using-artificial-intelligence-target-sleeper-bacteria-0408
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: press release. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 59 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.